ACS Chemical Neuroscience
June 7, 2022
Konstantin A. Demin, Olga V. Kupriyanova, Вадим А. Шевырин et al.
20 citations
Hallucinogenic drugs potently affect brain and behavior and have also recently emerged as potentially promising agents in pharmacotherapy. Complementing laboratory rodents, the zebrafish (Danio rerio) is a powerful animal model organism for screening neuroactive drugs, including hallucinogens. Here, we test a battery of ten novel N-benzyl-2-phenylethylamine (NBPEA) derivatives with the 2,4- and...
Pharmaceuticals
May 23, 2022
Danish Mahmood, Sattam Khulaif Alenezi, Md Jamir Anwar et al.
29 citations
Psychedelics such as lysergic acid diethylamide (LSD), psilocybin (magic mushrooms), and mescaline exhibit intense effects on the human brain and behaviour. In recent years, there has been a surge in studies investigating these drugs because clinical studies have shown that these once banned drugs are well tolerated and efficacious in medically supervised low doses called microdosing....
Frontiers in Psychiatry
March 25, 2022
David E. Nichols
65 citations
At first glance, it appears there is little difference between the molecular structures of methylenedioxymethamphetamine (MDMA), which has an N -methyl attached to its amino group, and methylenedioxyamphetamine (MDA), a primary amine that is recognized to have hallucinogenic activity. It is known from studies with other hallucinogenic amphetamines that N -methylation of hallucinogenic...
March 11, 2022
William E. Schreiber
This chapter highlights the similarities in chemical structure and physiologic effects of hallucinogens, as well as their metabolism, therapeutic uses and potential for misuse or abuse. Special attention is given to the testing process, with an emphasis on interpretation of test results. Hallucinogens are drugs that alter an individual's perception of reality. The classic hallucinogens include...
Family Practice
January 24, 2022
James Bailey Sanford
Dear Editor, We are in the midst of a so-called “psychedelic renaissance,” a time of renewed interest in the therapeutic potential of psychoactive drugs such as psilocybin, mescaline, and lysergic acid diethylamide. When they first emerged as topics of academic interest in the mid-20th century, these substances were greeted with exuberance for their apparent panacea-like effects in treating a...
bioRxiv (Cold Spring Harbor Laboratory)
January 21, 2022
Konstantin A. Demin, Olga V. Kupriyanova, Вадим А. Шевырин et al.
preprint
Abstract Serotonergic hallucinogenic drugs potently affect human brain and behavior, and have recently emerged as potentially promising agents in psychopharmacotherapy. Complementing rodent studies, zebrafish ( Danio rerio ) is a powerful animal model for screening neuroactive drugs, including serotonergic agents. Here, we test ten different N-Benzyl-2-phenylethylamine (NBPEA) derivatives with...
Current Topics in Behavioral Neurosciences
2022
Matthew W. Johnson
31 citations
This manuscript reviews research suggesting that classic psychedelics (5-HT2A receptor agonists) are effective in treating addictions including tobacco use disorder. I review historical research from the 1950s to 1970s suggesting that classic psychedelics are associated with addiction recovery across pharmacologically distinct drugs of addiction. I then review anthropological reports about...
Journal of Psychopharmacology
2022
Grant Jones, Matthew K. Nock
30 citations
Background: The United States boasts the largest prison population in the world, conferring significant direct and indirect costs (e.g. lost wages for the incarcerated, increased morbidity/mortality, etc.) to society. Recidivism rates are high for the imprisoned and most interventions to reduce criminality are minimally effective. Thus, in addition to the need for criminal justice reform, there...
The International Journal of Neuropsychopharmacology
December 3, 2021
Benjamin Hackl, Hannes Todt, Helmut Kubista et al.
11 citations
Abstract Psilocybin, a hallucinogen contained in “magic” mushrooms, holds great promise for the treatment of various psychiatric disorders, and early clinical trials are encouraging. Adverse cardiac events after intake of high doses of psilocybin and a trial reporting QT interval prolongation in the electrocardiogram attributed to the drug’s main metabolite, psilocin, gave rise to safety...
Journal of Neurochemistry
November 19, 2021
Samuel T. Slocum, Jeffrey F. Diberto, Bryan L. Roth
59 citations
Abstract A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin: the desire for additional approaches to mental health care, incremental progress in basic and clinical research, and the reconsideration and relaxation of existing drug policies. With the...